AU4525589A
(en)
*
|
1988-10-27 |
1990-05-14 |
Regents Of The University Of Minnesota |
Liposome immunoadjuvants containing il-2
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US5536642A
(en)
*
|
1993-09-09 |
1996-07-16 |
Barbera-Guillem; Emilio |
Diagnostic and prognostic methods for solid non-lymphoid tumors and their metastases
|
JPH09506866A
(ja)
*
|
1993-12-14 |
1997-07-08 |
ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン |
医薬として活性のある物質の免疫療法のための放出制御
|
US5635597A
(en)
*
|
1994-05-27 |
1997-06-03 |
Affymax Technologies, N.V. |
Peptides that bind IL-2 receptors
|
US5696234A
(en)
*
|
1994-08-01 |
1997-12-09 |
Schering Corporation |
Muteins of mammalian cytokine interleukin-13
|
US5641665A
(en)
|
1994-11-28 |
1997-06-24 |
Vical Incorporated |
Plasmids suitable for IL-2 expression
|
US6045788A
(en)
*
|
1996-02-28 |
2000-04-04 |
Cornell Research Foundation, Inc. |
Method of stimulation of immune response with low doses of IL-2
|
US6509313B1
(en)
|
1996-02-28 |
2003-01-21 |
Cornell Research Foundation, Inc. |
Stimulation of immune response with low doses of cytokines
|
US6790604B1
(en)
|
1998-05-12 |
2004-09-14 |
Stefan A. Cohen |
Methods for identifying or diagnosing carcinoma cells with metastatic potential based on the measurement of lymphoid genes or their products in carcinoma cells
|
US6955807B1
(en)
*
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
CA2405709A1
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20030143191A1
(en)
*
|
2001-05-25 |
2003-07-31 |
Adam Bell |
Chemokine beta-1 fusion proteins
|
JP2005507870A
(ja)
|
2001-08-13 |
2005-03-24 |
ユニバーシティ・オブ・サザン・カリフォルニア |
低毒性のインターロイキン−2突然変異体
|
CA2471363C
(en)
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
CA2513213C
(en)
|
2003-01-22 |
2013-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
JP2004256444A
(ja)
*
|
2003-02-26 |
2004-09-16 |
Kansai Tlo Kk |
悪性腫瘍の治療方法
|
DE602004031341D1
(de)
|
2003-07-21 |
2011-03-24 |
Transgene Sa |
Multifunktionelle cytokine
|
ES2359473T3
(es)
*
|
2003-07-21 |
2011-05-23 |
Transgene S.A. |
Citoquinas multifuncionales.
|
EP1694360B1
(de)
|
2003-11-04 |
2010-08-04 |
Novartis Vaccines and Diagnostics, Inc. |
Verwendung von antagonist-anti-cd40-antikörpern zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen und organtransplantat-abstossung
|
RU2006135112A
(ru)
*
|
2004-03-05 |
2008-04-10 |
Чирон Корпорейшн (Us) |
Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам
|
JP5855326B2
(ja)
|
2005-01-06 |
2016-02-09 |
ノヴォ ノルディスク アー/エス |
抗kir組み合わせ治療および方法
|
US7334361B2
(en)
*
|
2005-03-29 |
2008-02-26 |
Adaptive Micro Systems Llc |
Access system for a display panel assembly
|
CA2749539C
(en)
|
2009-01-21 |
2022-07-19 |
Amgen Inc. |
Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases
|
CU23734A1
(es)
|
2009-11-27 |
2011-11-15 |
Centro Inmunologia Molecular |
Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
DK3489255T3
(da)
|
2011-02-10 |
2021-08-23 |
Roche Glycart Ag |
Muterede interleukin-2-polypeptider
|
CN103476433A
(zh)
|
2011-02-10 |
2013-12-25 |
罗切格利卡特公司 |
改良的免疫疗法
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
HUE039577T2
(hu)
|
2011-06-01 |
2019-01-28 |
Intrexon Actobiotics Nv |
Policisztronos expressziós rendszer baktériumokhoz
|
US20130064811A1
(en)
*
|
2011-09-09 |
2013-03-14 |
International Business Machines Corporation |
Methods to Enhance Cancer Treatment
|
MX365382B
(es)
|
2012-08-07 |
2019-05-31 |
Roche Glycart Ag |
Una combinación de inmunoconjugado y anticuerpo para usarse en el tratamiento de cáncer.
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
AU2014232416B2
(en)
|
2013-03-15 |
2017-09-28 |
Xencor, Inc. |
Modulation of T Cells with Bispecific Antibodies and FC Fusions
|
CN106132422A
(zh)
|
2014-02-27 |
2016-11-16 |
莱斯拉公司 |
使用视黄酸受体相关孤儿受体γ的激动剂的过继细胞疗法&相关治疗方法
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
AU2015256190B2
(en)
|
2014-05-05 |
2019-08-15 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
|
EP3209641A4
(de)
|
2014-05-05 |
2018-06-06 |
Lycera Corporation |
Benzolsulfonamid und verwandte verbindungen zur verwendung als ror-agonisten und behandlung von erkrankungen
|
US10806773B2
(en)
|
2014-10-09 |
2020-10-20 |
Dana-Farber Cancer Institute, Inc. |
Multiple-variable IL-2 dose regimen for treating immune disorders
|
CA2982847A1
(en)
|
2015-05-05 |
2016-11-10 |
Lycera Corporation |
Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
|
KR20180025894A
(ko)
|
2015-06-11 |
2018-03-09 |
라이세라 코퍼레이션 |
Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
|
EP3178848A1
(de)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
|
CN115920030A
(zh)
|
2015-12-09 |
2023-04-07 |
豪夫迈·罗氏有限公司 |
Ii型抗cd20抗体用于降低抗药物抗体形成
|
EP3402499B1
(de)
|
2016-01-14 |
2021-07-21 |
Intrexon Actobiotics NV |
Zusammensetzungen und verfahren zur behandlung von typ-1-diabetes
|
JP7461741B2
(ja)
|
2016-06-20 |
2024-04-04 |
カイマブ・リミテッド |
抗pd-l1およびil-2サイトカイン
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
WO2018073365A1
(en)
|
2016-10-19 |
2018-04-26 |
F. Hoffmann-La Roche Ag |
Method for producing an immunoconjugate
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
CA3056630A1
(en)
|
2017-03-15 |
2018-09-20 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
WO2018184965A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
KR102461885B1
(ko)
|
2017-04-03 |
2022-11-03 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
CA3064435A1
(en)
|
2017-05-24 |
2018-11-29 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
AU2018300069A1
(en)
|
2017-07-11 |
2020-02-27 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
US20200181220A1
(en)
|
2017-08-03 |
2020-06-11 |
Synthorx, Inc. |
Cytokine conjugates for the treatment of proliferative and infectious diseases
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
EP3762406A2
(de)
|
2018-03-09 |
2021-01-13 |
Askgene Pharma, Inc. |
Zytokin-prodrugs
|
KR20210025522A
(ko)
|
2018-06-25 |
2021-03-09 |
유니버시티 오브 워싱톤 |
강력하고 선택적인 인터루킨 모방체의 드 노보 디자인
|
MX2020007072A
(es)
|
2018-09-17 |
2020-11-11 |
Gi Innovation Inc |
Proteina de fusion que comprende proteina il-2 y proteina cd80 y uso de la misma.
|
BR112021012027A2
(pt)
|
2018-12-21 |
2021-11-03 |
Ose Immunotherapeutics |
Molécula bifuncional direcionada contra pd-1 humano
|
CN114949240A
(zh)
|
2019-02-06 |
2022-08-30 |
新索思股份有限公司 |
Il-2缀合物及其使用方法
|
CN111944036A
(zh)
|
2019-05-14 |
2020-11-17 |
上海盖浦生物科技有限公司 |
一种增殖免疫细胞的突变体蛋白
|
MX2021014189A
(es)
|
2019-05-20 |
2022-01-06 |
Cytune Pharma |
Regimenes de dosificacion de agonistas de la il-2/il-15r?y para el tratamiento del cancer o enfermedades infecciosas.
|
BR112021023345A2
(pt)
|
2019-05-20 |
2022-02-01 |
Pandion Operations Inc |
Imunotolerância com alvo em madcam
|
CN114341189A
(zh)
|
2019-06-12 |
2022-04-12 |
奥美药业有限公司 |
全新il-15前药及其应用
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
CN114761028A
(zh)
|
2019-09-27 |
2022-07-15 |
英特瑞克斯顿阿克图比奥帝克斯有限公司 |
乳糜泻的治疗
|
KR102400884B1
(ko)
|
2019-11-15 |
2022-05-23 |
주식회사 제넥신 |
변형된 인터루킨-7 및 인터루킨-2를 포함하는 융합단백질 및 이의 용도
|
JP7381750B2
(ja)
*
|
2019-11-20 |
2023-11-15 |
ジーアイ・セル・インコーポレイテッド |
ナチュラルキラー細胞培養用組成物及びこれを用いたナチュラルキラー細胞の製造方法
|
CN114829585A
(zh)
|
2019-11-20 |
2022-07-29 |
吉爱希公司 |
用于培养t细胞的组合物及使用其来培养t细胞的方法
|
IL291909A
(en)
|
2019-11-20 |
2022-06-01 |
Gi Cell Inc |
The composition of T regulatory cell culture and its use
|
BR112022010246A2
(pt)
|
2019-11-27 |
2022-09-06 |
Gi Innovation Inc |
Composição farmacêutica para o tratamento de câncer compreendendo proteína de fusão compreendendo proteína il-2 e proteína cd80 e inibidor de checkpoint imunológico
|
MX2022006295A
(es)
|
2019-11-27 |
2022-06-08 |
Gi Cell Inc |
Composicion para el tratamiento anticancerigeno, que comprende celulas nk y proteina de fusion que comprende la proteina il-2 y la proteina cd80.
|
CN115297881A
(zh)
|
2020-03-18 |
2022-11-04 |
Gi 医诺微新 |
包含含有il-2蛋白和cd80蛋白的融合蛋白和抗癌药物的用于治疗癌症的药物组合物
|
CN115989238A
(zh)
|
2020-03-18 |
2023-04-18 |
Gi医诺微新 |
包含il-2蛋白和cd80蛋白片段或其变体的融合蛋白及其用途
|
WO2021187897A1
(ko)
|
2020-03-18 |
2021-09-23 |
(주)지아이이노베이션 |
Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 제제
|
KR20230004682A
(ko)
|
2020-04-22 |
2023-01-06 |
머크 샤프 앤드 돔 엘엘씨 |
인터류킨-2 수용체 베타 감마c 이량체에 대해 편향되고 비펩티드성 수용성 중합체에 접합된 인간 인터류킨-2 접합체
|
KR102373965B1
(ko)
|
2020-06-05 |
2022-03-15 |
(주)지아이이노베이션 |
Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물
|
EP4174088A4
(de)
|
2020-06-30 |
2024-01-24 |
Gi Innovation Inc |
Fusionsprotein mit anti-lag-3-antikörper und il-2 sowie verwendung davon
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
EP4232069A1
(de)
|
2020-10-26 |
2023-08-30 |
Cytune Pharma |
Il-2/il-15rbetagamma-agonist zur behandlung von plattenepithelkarzinom
|
EP4232068A1
(de)
|
2020-10-26 |
2023-08-30 |
Cytune Pharma |
Il-2/il-15rbetagamma-agonist zur behandlung von nichtmelanom-hautkrebs
|
EP4255923A2
(de)
|
2020-12-04 |
2023-10-11 |
F. Hoffmann-La Roche AG |
Ph-abhängige mutante interleukin-2-polypeptide
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
WO2022200525A1
(en)
|
2021-03-26 |
2022-09-29 |
Innate Pharma |
Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
|
CN117157312A
(zh)
|
2021-03-30 |
2023-12-01 |
豪夫迈·罗氏有限公司 |
蛋白酶活化的多肽
|
IL307419A
(en)
|
2021-04-09 |
2023-12-01 |
Ose Immunotherapeutics |
A new scaffold for bifunctional molecules with improved properties
|
CN115867645A
(zh)
|
2021-05-18 |
2023-03-28 |
赛斯尔擎生物技术(上海)有限公司 |
修饰细胞的方法
|
EP4352098A1
(de)
|
2021-06-09 |
2024-04-17 |
Innate Pharma |
Multispezifische proteine, die an nkp46, einen cytokinrezeptor, ein tumorantigen und cd16a binden
|
IL308531A
(en)
|
2021-06-09 |
2024-01-01 |
Innate Pharma |
Multiple specific antibodies that bind to CD20, NKP46, CD16 and are equipped with IL-2
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
WO2022266467A2
(en)
|
2021-06-17 |
2022-12-22 |
Dana-Farber Cancer Institute, Inc. |
Recombinant histone polypeptide and uses thereof
|
KR20240043797A
(ko)
|
2021-08-13 |
2024-04-03 |
싸이튠 파마 |
암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합
|
WO2024068705A1
(en)
|
2022-09-29 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Protease-activated polypeptides
|